Charles River Laboratories International, Inc. Logo

Charles River Laboratories International, Inc.

CRL

(2.5)
Stock Price

187,74 USD

10.61% ROA

12.11% ROE

22.31x PER

Market Cap.

9.646.163.681,00 USD

64.09% DER

0% Yield

10.59% NPM

Charles River Laboratories International, Inc. Stock Analysis

Charles River Laboratories International, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Charles River Laboratories International, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (16.18%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

5 PBV

The stock's PBV ratio (2.98x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (1.836), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

7 DER

The company has a high debt to equity ratio (107%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

10 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

11 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

Charles River Laboratories International, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Charles River Laboratories International, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Charles River Laboratories International, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Charles River Laboratories International, Inc. Revenue
Year Revenue Growth
1998 193.301.000
1999 219.276.000 11.85%
2000 306.585.000 28.48%
2001 465.630.000 34.16%
2002 554.629.000 16.05%
2003 613.723.000 9.63%
2004 766.917.000 19.98%
2005 1.122.228.000 31.66%
2006 1.058.385.000 -6.03%
2007 1.230.626.000 14%
2008 1.343.493.000 8.4%
2009 1.202.551.000 -11.72%
2010 1.133.416.000 -6.1%
2011 1.142.647.000 0.81%
2012 1.129.530.000 -1.16%
2013 1.165.528.000 3.09%
2014 1.297.662.000 10.18%
2015 1.363.302.000 4.81%
2016 1.681.432.000 18.92%
2017 1.857.601.000 9.48%
2018 2.266.096.000 18.03%
2019 2.621.226.000 13.55%
2020 2.923.933.000 10.35%
2021 3.540.160.000 17.41%
2022 3.976.060.000 10.96%
2023 4.106.492.000 3.18%
2023 4.129.409.000 0.55%
2024 4.104.468.000 -0.61%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Charles River Laboratories International, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Charles River Laboratories International, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Charles River Laboratories International, Inc. EBITDA
Year EBITDA Growth
1998 46.278.000
1999 56.609.000 18.25%
2000 82.835.000 31.66%
2001 118.361.000 30.01%
2002 146.771.000 19.36%
2003 168.891.000 13.1%
2004 207.776.000 18.71%
2005 285.830.000 27.31%
2006 272.322.000 -4.96%
2007 317.555.000 14.24%
2008 986.480.000 67.81%
2009 193.287.000 -410.37%
2010 122.271.000 -58.08%
2011 196.102.000 37.65%
2012 183.833.000 -6.67%
2013 169.207.000 -8.64%
2014 203.627.000 16.9%
2015 230.678.000 11.73%
2016 292.329.000 21.09%
2017 368.102.000 20.58%
2018 410.283.000 10.28%
2019 563.061.000 27.13%
2020 768.471.000 26.73%
2021 820.160.000 6.3%
2022 986.148.000 16.83%
2023 901.940.000 -9.34%
2023 1.032.118.000 12.61%
2024 1.022.756.000 -0.92%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Charles River Laboratories International, Inc. Gross Profit
Year Gross Profit Growth
1998 70.754.000
1999 98.371.000 28.07%
2000 135.135.000 27.21%
2001 167.251.000 19.2%
2002 208.983.000 19.97%
2003 233.665.000 10.56%
2004 298.566.000 21.74%
2005 428.735.000 30.36%
2006 406.607.000 -5.44%
2007 478.191.000 14.97%
2008 510.709.000 6.37%
2009 429.368.000 -18.94%
2010 384.760.000 -11.59%
2011 402.242.000 4.35%
2012 392.081.000 -2.59%
2013 394.902.000 0.71%
2014 472.660.000 16.45%
2015 531.092.000 11%
2016 646.666.000 17.87%
2017 702.314.000 7.92%
2018 840.067.000 16.4%
2019 958.311.000 12.34%
2020 1.073.541.000 10.73%
2021 1.334.638.000 19.56%
2022 1.462.651.000 8.75%
2023 1.447.360.000 -1.06%
2023 1.502.556.000 3.67%
2024 1.341.848.000 -11.98%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Charles River Laboratories International, Inc. Net Profit
Year Net Profit Growth
1998 23.378.000
1999 17.124.000 -36.52%
2000 -11.224.000 252.57%
2001 35.407.000 131.7%
2002 50.132.000 29.37%
2003 80.151.000 37.45%
2004 89.792.000 10.74%
2005 141.999.000 36.77%
2006 -55.783.000 354.56%
2007 154.406.000 136.13%
2008 -521.843.000 129.59%
2009 114.441.000 555.99%
2010 -336.669.000 133.99%
2011 109.566.000 407.28%
2012 97.295.000 -12.61%
2013 102.828.000 5.38%
2014 126.698.000 18.84%
2015 149.313.000 15.15%
2016 154.765.000 3.52%
2017 123.355.000 -25.46%
2018 226.373.000 45.51%
2019 252.019.000 10.18%
2020 364.304.000 30.82%
2021 390.982.000 6.82%
2022 486.226.000 19.59%
2023 349.556.000 -39.1%
2023 474.624.000 26.35%
2024 359.952.000 -31.86%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Charles River Laboratories International, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 2
1999 1 0%
2000 0 0%
2001 1 0%
2002 1 100%
2003 2 0%
2004 2 0%
2005 2 50%
2006 -1 0%
2007 2 100%
2008 -8 128.57%
2009 2 800%
2010 -5 120%
2011 2 350%
2012 2 0%
2013 2 0%
2014 3 0%
2015 3 33.33%
2016 3 0%
2017 3 -50%
2018 5 50%
2019 5 20%
2020 7 28.57%
2021 8 0%
2022 10 22.22%
2023 7 -50%
2023 9 33.33%
2024 7 -28.57%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Charles River Laboratories International, Inc. Free Cashflow
Year Free Cashflow Growth
1998 25.471.000
1999 24.617.000 -3.47%
2000 18.203.000 -35.24%
2001 34.642.000 47.45%
2002 96.116.000 63.96%
2003 91.062.000 -5.55%
2004 139.491.000 34.72%
2005 141.152.000 1.18%
2006 -17.377.000 912.29%
2007 57.212.000 130.37%
2008 82.868.000 30.96%
2009 145.032.000 42.86%
2010 126.153.000 -14.97%
2011 156.140.000 19.21%
2012 160.366.000 2.64%
2013 167.985.000 4.54%
2014 194.126.000 13.47%
2015 223.106.000 12.99%
2016 243.031.000 8.2%
2017 233.834.000 -3.93%
2018 301.086.000 22.34%
2019 340.422.000 11.56%
2020 380.015.000 10.42%
2021 532.027.000 28.57%
2022 294.907.000 -80.41%
2023 139.503.000 -111.4%
2023 365.370.000 61.82%
2024 154.049.000 -137.18%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Charles River Laboratories International, Inc. Operating Cashflow
Year Operating Cashflow Growth
1998 37.380.000
1999 37.568.000 0.5%
2000 33.768.000 -11.25%
2001 71.298.000 52.64%
2002 133.659.000 46.66%
2003 123.766.000 -7.99%
2004 184.827.000 33.04%
2005 236.702.000 21.92%
2006 164.370.000 -44.01%
2007 284.248.000 42.17%
2008 279.949.000 -1.54%
2009 225.044.000 -24.4%
2010 169.013.000 -33.15%
2011 205.283.000 17.67%
2012 207.900.000 1.26%
2013 207.139.000 -0.37%
2014 251.051.000 17.49%
2015 286.358.000 12.33%
2016 298.319.000 4.01%
2017 316.265.000 5.67%
2018 441.140.000 28.31%
2019 480.936.000 8.27%
2020 546.575.000 12.01%
2021 760.799.000 28.16%
2022 619.640.000 -22.78%
2023 205.450.000 -201.6%
2023 683.898.000 69.96%
2024 193.535.000 -253.37%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Charles River Laboratories International, Inc. Capital Expenditure
Year Capital Expenditure Growth
1998 11.909.000
1999 12.951.000 8.05%
2000 15.565.000 16.79%
2001 36.656.000 57.54%
2002 37.543.000 2.36%
2003 32.704.000 -14.8%
2004 45.336.000 27.86%
2005 95.550.000 52.55%
2006 181.747.000 47.43%
2007 227.036.000 19.95%
2008 197.081.000 -15.2%
2009 80.012.000 -146.31%
2010 42.860.000 -86.68%
2011 49.143.000 12.79%
2012 47.534.000 -3.38%
2013 39.154.000 -21.4%
2014 56.925.000 31.22%
2015 63.252.000 10%
2016 55.288.000 -14.4%
2017 82.431.000 32.93%
2018 140.054.000 41.14%
2019 140.514.000 0.33%
2020 166.560.000 15.64%
2021 228.772.000 27.19%
2022 324.733.000 29.55%
2023 65.947.000 -392.42%
2023 318.528.000 79.3%
2024 39.486.000 -706.69%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Charles River Laboratories International, Inc. Equity
Year Equity Growth
1998 168.565.000
1999 -109.838.000 253.47%
2000 130.257.000 184.32%
2001 302.498.000 56.94%
2002 375.943.000 19.54%
2003 474.799.000 20.82%
2004 1.482.297.000 67.97%
2005 1.836.731.000 19.3%
2006 1.604.434.000 -14.48%
2007 1.863.967.000 13.92%
2008 1.199.447.000 -55.4%
2009 1.372.405.000 12.6%
2010 688.727.000 -99.27%
2011 529.143.000 -30.16%
2012 603.200.000 12.28%
2013 664.658.000 9.25%
2014 704.346.000 5.63%
2015 765.564.000 8%
2016 853.784.000 10.33%
2017 1.064.016.000 19.76%
2018 1.338.303.000 20.5%
2019 1.666.475.000 19.69%
2020 2.143.668.000 22.26%
2021 2.591.992.000 17.3%
2022 3.023.505.000 14.27%
2023 3.350.709.000 9.77%
2023 3.658.998.000 8.43%
2024 3.773.094.000 3.02%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Charles River Laboratories International, Inc. Assets
Year Assets Growth
1998 234.254.000
1999 363.056.000 35.48%
2000 410.608.000 11.58%
2001 571.362.000 28.14%
2002 701.344.000 18.53%
2003 799.554.000 12.28%
2004 2.626.835.000 69.56%
2005 2.538.209.000 -3.49%
2006 2.557.544.000 0.76%
2007 2.805.537.000 8.84%
2008 2.159.918.000 -29.89%
2009 2.204.093.000 2%
2010 1.733.373.000 -27.16%
2011 1.558.320.000 -11.23%
2012 1.586.344.000 1.77%
2013 1.644.621.000 3.54%
2014 1.885.192.000 12.76%
2015 2.068.497.000 8.86%
2016 2.711.800.000 23.72%
2017 2.929.922.000 7.44%
2018 3.855.879.000 24.01%
2019 4.692.790.000 17.83%
2020 5.490.831.000 14.53%
2021 7.024.292.000 21.83%
2022 7.602.770.000 7.61%
2023 7.607.007.000 0.06%
2023 8.195.001.000 7.18%
2024 7.948.283.000 -3.1%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Charles River Laboratories International, Inc. Liabilities
Year Liabilities Growth
1998 65.689.000
1999 472.894.000 86.11%
2000 280.351.000 -68.68%
2001 268.864.000 -4.27%
2002 325.401.000 17.37%
2003 324.755.000 -0.2%
2004 1.144.538.000 71.63%
2005 701.478.000 -63.16%
2006 953.110.000 26.4%
2007 941.570.000 -1.23%
2008 960.471.000 1.97%
2009 830.269.000 -15.68%
2010 1.044.646.000 20.52%
2011 1.029.177.000 -1.5%
2012 983.144.000 -4.68%
2013 979.963.000 -0.32%
2014 1.180.846.000 17.01%
2015 1.302.933.000 9.37%
2016 1.858.016.000 29.88%
2017 1.865.906.000 0.42%
2018 2.517.576.000 25.88%
2019 3.026.315.000 16.81%
2020 3.347.163.000 9.59%
2021 4.432.300.000 24.48%
2022 4.579.265.000 3.21%
2023 4.256.298.000 -7.59%
2023 4.536.003.000 6.17%
2024 4.175.189.000 -8.64%

Charles River Laboratories International, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
79.1
Net Income per Share
8.38
Price to Earning Ratio
22.31x
Price To Sales Ratio
2.37x
POCF Ratio
12.84
PFCF Ratio
19.81
Price to Book Ratio
2.59
EV to Sales
3.02
EV Over EBITDA
11.92
EV to Operating CashFlow
16.41
EV to FreeCashFlow
25.28
Earnings Yield
0.04
FreeCashFlow Yield
0.05
Market Cap
9,65 Bil.
Enterprise Value
12,31 Bil.
Graham Number
116.66
Graham NetNet
-63.03

Income Statement Metrics

Net Income per Share
8.38
Income Quality
1.7
ROE
0.12
Return On Assets
0.05
Return On Capital Employed
0.09
Net Income per EBT
0.8
EBT Per Ebit
0.9
Ebit per Revenue
0.15
Effective Tax Rate
0.17

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.34
Operating Profit Margin
0.15
Pretax Profit Margin
0.13
Net Profit Margin
0.11

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
14.55
Free CashFlow per Share
9.45
Capex to Operating CashFlow
0.35
Capex to Revenue
0.06
Capex to Depreciation
0.79
Return on Invested Capital
0.08
Return on Tangible Assets
0.11
Days Sales Outstanding
68.23
Days Payables Outstanding
18.02
Days of Inventory on Hand
47.26
Receivables Turnover
5.35
Payables Turnover
20.26
Inventory Turnover
7.72
Capex per Share
5.1

Balance Sheet

Cash per Share
3,48
Book Value per Share
73,19
Tangible Book Value per Share
-2.07
Shareholders Equity per Share
72.21
Interest Debt per Share
48.9
Debt to Equity
0.64
Debt to Assets
0.3
Net Debt to EBITDA
2.58
Current Ratio
1.58
Tangible Asset Value
-0,11 Bil.
Net Current Asset Value
-2,68 Bil.
Invested Capital
6431618000
Working Capital
0,55 Bil.
Intangibles to Total Assets
0.49
Average Receivables
0,77 Bil.
Average Payables
0,13 Bil.
Average Inventory
355196000
Debt to Market Cap
0.25

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Charles River Laboratories International, Inc. Dividends
Year Dividends Growth

Charles River Laboratories International, Inc. Profile

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

CEO
Mr. James C. Foster J.D.
Employee
20.400
Address
251 Ballardvale Street
Wilmington, 01887

Charles River Laboratories International, Inc. Executives & BODs

Charles River Laboratories International, Inc. Executives & BODs
# Name Age
1 Mr. Mark Mintz
Corporate Senior Vice President & Chief Information Officer
70
2 Prof. Julie Frearson Ph.D.
Corporate Senior Vice President & Chief Scientific Officer
70
3 Mr. James C. Foster J.D.
Chief Executive Officer, President & Chairman
70
4 Mr. William D. Barbo
Corporate Executive Vice President of Community Relations
70
5 Mr. Michael Gunnar Knell
Corporate Senior Vice President & Chief Accounting Officer
70
6 Todd Spencer
Corporate Vice President of Investor Relations
70
7 Mr. Matthew L. Daniel
Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer
70
8 Ms. Flavia H. Pease
Corporate Executive Vice President & Chief Financial Officer
70
9 Ms. Birgit Girshick
Corporate Executive Vice President & Chief Operating Officer
70
10 Mr. Joseph W. LaPlume
Corporate Executive Vice President of Corporate Development & Strategy
70

Charles River Laboratories International, Inc. Competitors